Replies to post #451 on Halozyme Therapeutics Inc (HALO)

[rkrw]

I don't think its going to be inferior to biodel, lets just leave it at that.

Probably talking a $300M investment to bring cheetah to market on their own, p2 and multiple p3 trials, phase iv marketing studies, various devices, sales and marketing, a couple of years to break even on sales, manufacturing plant. After all that as a new player in an established market, they could spend all that and fall on their face. I see slim to none chance they take it all the way on their own.